Supplemental Online Content

Juraschek SP, Hu J, Cluett JL, et al. Orthostatic hypotension, hypertension treatment, and cardiovascular disease: an individual participant meta-analysis. *JAMA*. Published online October 17, 2023. doi:10.1001/jama.2023.18497

eAppendix. Details of search strategies

eFigure 1. PRISMA diagram of the updated systematic review

eFigure 2. Updated meta-analysis of the effects of hypertension treatment on orthostatic hypotension.

eFigure 3. Cumulative incidence of cardiovascular disease or all-cause mortality by treatment assignment and orthostatic hypotension status

eFigure 4. Cumulative incidence of cardiovascular disease or all-cause mortality by treatment assignment and standing hypotension status

eFigure 5. Restricted cubic spline of difference in diastolic blood pressure or standing blood pressure

eFigure 6. Fully adjusted splines of difference in systolic blood pressure or standing blood pressure

eFigure 7. Fully adjusted splines of difference in diastolic blood pressure or standing blood pressure

eFigure 8. Two-stage meta-analysis, orthostatic hypotension and cardiovascular disease or all-cause mortality

eFigure 9. Two-stage meta-analysis, orthostatic hypotension and all-cause mortality

eFigure 10. Two-stage meta-analysis, standing hypotension and cardiovascular disease or all-cause mortality

eFigure 11. Two-stage meta-analysis, standing hypotension and all-cause mortality

eTable 1. Comparison of covariate definitions across blood pressure treatment goal trials

eTable 2. Comparison of covariate definitions across placebo-controlled trials

eTable 3. Participant characteristics for all trials, trials of blood pressure treatment goal, and placebo-controlled trials

eTable 4. Cross-tabulation of orthostatic hypotension and standing hypotension

eTable 5. Baseline characteristics of each blood pressure treatment goal trial

eTable 6. Baseline characteristics of each placebo-controlled trial

eTable 7. Number of participants by blood pressure distribution

eTable 8. Association of baseline orthostatic hypotension with cardiovascular disease or all-cause mortality

eTable 9. Association of baseline standing hypotension with cardiovascular disease or all-cause mortality

eTable 10. Association of baseline orthostatic hypotension with cardiovascular disease or all-cause mortality adjusted for additional cardiovascular risk factors

eTable 11. Association of baseline standing hypotension with cardiovascular disease or all-cause mortality adjusted for additional cardiovascular risk factors

eTable 12. Association between orthostatic or standing hypotension and outcomes among those assigned a more intensive blood pressure goal or active treatment

eTable 13. Association between orthostatic or standing hypotension and outcomes among those assigned a standard blood pressure goal or placebo

eTable 14. Treatment effects on cardiovascular disease or all-cause mortality by baseline orthostatic hypotension, unadjusted

eTable 15. Treatment effects on cardiovascular disease or all-cause mortality by baseline standing hypotension, unadjusted

eTable 16. Treatment effects on cardiovascular disease or all-cause mortality by baseline orthostatic hypotension, adjusted for additional cardiovascular risk factors

eTable 17. Treatment effects on cardiovascular disease or all-cause mortality by baseline standing hypotension, adjusted for additional cardiovascular risk factors

eTable 18. Association of baseline orthostatic hypotension with cardiovascular disease or all-cause mortality, using an alternate definition of orthostatic hypotension based on a drop in systolic blood pressure of at least 30 mm Hg or a drop in diastolic blood pressure of at least 10 mm Hg

eTable 19. Treatment effects on cardiovascular disease or all-cause mortality by baseline orthostatic hypotension, using an alternate definition of orthostatic hypotension based on a drop in systolic blood pressure of at least 30 mm Hg or a drop in diastolic blood pressure of at least 10 mm Hg

eTable 20. Treatment effects on cardiovascular disease or all-cause mortality by baseline standing hypotension, defined using distinct thresholds for systolic or diastolic blood pressure

eTable 21. Treatment effects among participants with baseline orthostatic hypotension or baseline standing hypotension in strata of baseline characteristics

This supplemental material has been provided by the authors to give readers additional information about their work.

eAppendix. Details of search strategies

PUBMED SEARCH:

Hypertension, Orthostatic Hypotension (RCTs / mortality)

Search update May 13, 2022

Medline / PubMed (National Library of Medicine, NCBI)

("Hypertension"[Mesh:NoExp] OR "Essential Hypertension"[Mesh] OR "Prehypertension"[Mesh] OR hypertension[tiab] OR high blood pressure[tiab] OR prehypertension[tiab])

AND

("Hypertension/drug therapy"[Mesh] OR "Antihypertensive Agents" [Pharmacological Action] OR "Antihypertensive Agents"[Mesh] OR anti hypertensive*[tiab] OR antihypertensive*[tiab] OR blood pressure lowering[tiab] OR BP lowering[tiab] OR drug therapy[tiab] OR acetazolamide[tiab] OR amiloride[tiab] OR amlodipine[tiab] OR drug therapy[tiab] OR benazepril[tiab] OR bisoprolol[tiab] OR bumetanide[tiab] OR candesartan[tiab] OR captopril[tiab] OR carvedilol[tiab] OR chlorthalidone[tiab] OR clonidine[tiab] OR diltiazem[tiab] OR doxazosin[tiab] OR ethacrynic acid[tiab] OR clonidine[tiab] OR fosinopril[tiab] OR furosemide[tiab] OR hydralazine[tiab] OR hydrochlorothiazide[tiab] OR indapamide[tiab] OR irbesartan[tiab] OR losartan[tiab] OR metoprolol[tiab] OR metolazone [tiab] OR minoxidil[tiab] OR losartan[tiab] OR nebivolol[tiab] OR nifedipine[tiab] OR olmesartan[tiab] OR perindopril[tiab] OR pindolol[tiab] OR prazosin[tiab] OR propranolol[tiab] OR telmisartan[tiab] OR spironolactone[tiab] OR terazosin[tiab] OR torsemide[tiab] OR telmisartan[tiab] OR timolol[tiab] OR trandolapril[tiab] OR triamterene[tiab] OR verapamil[tiab] OR timolol[tiab] OR trandolapril[tiab] OR triamterene[tiab] OR

AND

("Orthostatic Intolerance"[Mesh:NoExp] OR "Hypotension, Orthostatic"[Mesh] OR "Syncope, Vasovagal"[Mesh] OR orthostatic hypotension[tiab] OR orthostatic intolerance[tiab] OR postural hypotension[tiab] OR standing blood pressure[tiab] OR standing hypotension [tiab] OR syncope[tiab])

AND

("Randomized Controlled Trials as Topic"[Mesh] OR "Randomized Controlled Trial" [Publication Type] OR "Random Allocation"[Mesh] OR "Placebos"[Mesh] OR random*[tiab] OR placebo[tiab]) 366 results May 13, 2022

Embase (Elsevier, Embase-com)

Advanced Search

Remove mapping options

Source: Embase (1974-)

Restrict to Publication Types: Article, Conference Paper

#1)

'hypertension'/de OR 'borderline hypertension'/de OR 'diabetic hypertension'/de OR 'essential hypertension'/de OR 'orthostatic hypertension'/de OR 'prehypertension'/de OR 'systolic hypertension'/de OR hypertension:ab,ti OR 'high blood pressure':ab,ti OR prehypertension:ab,ti

#2)

'antihypertensive agent'/exp/mj OR 'anti hypertensive*':ab,ti OR antihypertensive*:ab,ti OR 'blood pressure lowering':ab,ti OR 'BP lowering':ab,ti OR acetazolamide:ab,ti OR amiloride:ab,ti OR amlodipine:ab,ti OR atenolol:ab,ti OR benazepril:ab,ti OR bisoprolol:ab,ti OR bumetanide:ab,ti OR candesartan:ab,ti OR captopril:ab,ti OR carvedilol:ab,ti OR chlorthalidone:ab,ti OR clonidine:ab,ti OR diltiazem:ab,ti OR doxazosin:ab,ti OR 'ethacrynic acid':ab,ti OR enalapril:ab,ti OR felodipine:ab,ti OR fosinopril:ab,ti OR furosemide:ab,ti OR hydralazine:ab,ti OR hydrochlorothiazide:ab,ti OR indapamide:ab,ti OR irbesartan:ab,ti OR lisinopril:ab,ti OR losartan:ab,ti OR metoprolol:ab,ti OR metolazone:ab,ti OR minoxidil:ab,ti OR perindopril:ab,ti OR pindolol:ab,ti OR prazosin:ab,ti OR propranolol:ab,ti OR quinapril:ab,ti OR ramipril:ab,ti OR spironolactone:ab,ti OR terazosin:ab,ti OR torsemide:ab,ti OR telmisartan:ab,ti OR timolol:ab,ti OR trandolapril:ab,ti OR triamterene:ab,ti OR verapamil:ab,ti

#3)

'orthostatic intolerance'/de OR 'orthostatic hypotension'/de OR 'faintness'/de OR 'orthostatic hypotension':ab,ti OR 'orthostatic intolerance':ab,ti OR 'postural hypotension':ab,ti OR 'standing blood pressure':ab,ti OR 'standing hypotension':ab,ti OR syncope:ab,ti

#4)

'randomized controlled trial'/exp OR 'randomized controlled trial (topic)'/de OR 'randomization'/exp OR 'placebo'/de OR random*:ab,ti OR placebo:ab,ti

(#1 AND #2 AND #3 AND #4)

746 results May 13, 2022

Cochrane Central Register of Controlled Trials (Cochrane Library, Wiley)

Advanced Search

search in title abstract keywords:

hypertension OR "high blood pressure" OR prehypertension

AND

"anti hypertensive" OR "anti hypertensives" OR antihypertensive* OR "blood pressure lowering" OR "BP lowering" OR acetazolamide OR amiloride OR amlodipine OR atenolol OR benazepril OR bisoprolol OR bumetanide OR candesartan OR captopril OR carvedilol OR chlorthalidone OR clonidine OR diltiazem OR doxazosin OR "ethacrynic acid" OR enalapril OR felodipine OR fosinopril OR furosemide OR hydralazine OR hydrochlorothiazide OR indapamide OR irbesartan OR lisinopril OR losartan OR metoprolol OR metolazone OR minoxidil OR moexipril OR nadolol OR nebivolol OR nifedipine OR olmesartan OR perindopril OR pindolol OR prazosin OR propranolol OR quinapril OR ramipril OR spironolactone OR terazosin OR torsemide OR telmisartan OR timolol OR trandolapril OR triamterene OR verapamil

AND

"orthostatic hypotension" OR "orthostatic intolerance" OR "postural hypotension" OR "standing blood pressure" OR "standing hypotension" OR syncope

475 results May 13, 2022

Note there were fewer articles identified from Cochrane Central due to a refinement in the search strategy that removed the "AND random* OR placebo" line.

© 2023 American Medical Association. All rights reserved.

Summary

PubMed 366 Embase 746


Cochrane Central 475

1587 references across all databases

52 new unique references retrieved from search May 13, 2022.

7 duplicates identified during import to Covidence: 45 new references for screening at title and abstract level


eFigure 1. PRISMA diagram of the updated systematic review



A. Trials Comparing Two Blood Pressure Treatment Goals

© 2023 American Medical Association. All rights reserved.


eFigure 2. Updated meta-analysis of the effects of hypertension treatment on orthostatic hypotension



This was updated from the Juraschek et al, *Annals of Internal Medicine* 2020 manuscript. Note that an additional visit file was found for the SPS3 trial, which increased the total number of assessments included in the meta-analysis.


eFigure 3. Cumulative incidence of cardiovascular disease or all-cause mortality by treatment assignment and orthostatic hypotension status

Follow-up data across the 9 trials censored at 5-years for (A) CVD or all-cause mortality or (B) All-cause mortality. The number at risk each year of follow-up is tabulated below each figure. Abbreviations: CVD, cardiovascular disease; Low/Act represents a low blood pressure goal or active treatment assignment; OH represents orthostatic hypotension; Std/Pla represents a standard goal or placebo assignment




eFigure 4. Cumulative incidence of cardiovascular disease or all-cause mortality by treatment assignment and orthostatic hypotension status

Follow-up data across the 9 trials censored at 5-years for (A) CVD or all-cause mortality or (B) All-cause mortality. The number at risk each year of follow-up is tabulated below each figure. Abbreviations: CVD, cardiovascular disease; HYP represents standing hypotension; Low/Act represents a low blood pressure goal or active treatment assignment; Std/Pla represents a standard goal or placebo assignment




eFigure 5. Restricted cubic spline of difference in diastolic blood pressure or standing blood pressure

Adjusted hazard ratios by treatment status for change in diastolic blood pressure (DBP) with (A) cardiovascular disease or death or (B) all-cause mortality as well as for standing systolic blood pressure with (C) cardiovascular disease or death or (D) all-cause mortality, using a restricted cubic spline with 4 knots determined by Harrell's method. Figures are based on data from all nine trials. Shade represents 95% confidence intervals. Both models were expressed relative to the median value and were truncated at the 2.5th and 97.5th percentiles. Models were adjusted for age, sex, and study. The hazard ratios are shown on a natural log scale. Included are kernel density plots, representing the distribution of change in DBP or standing DBP by treatment and by outcome status: low goal/active treatment, no outcome (blue, thick), low goal/active treatment outcome (blue, thin), standard goal/placebo, no outcome (red, thick), and standard goal/placebo, outcome (red, thin).




eFigure 6. Fully adjusted splines of difference in systolic blood pressure or standing blood pressure

Adjusted hazard ratios by treatment status for change in systolic blood pressure (SBP) with (A) cardiovascular disease or death or (B) all-cause mortality as well as for standing systolic blood pressure with (C) cardiovascular disease or death or (D) all-cause mortality, using a restricted cubic spline with 4 knots determined by Harrell's method. Figures are based on data from all nine trials. Shade represents 95% confidence intervals. Both models were expressed relative to the median value and were truncated at the 2.5th and 97.5th percentiles. Models were adjusted for age, sex, study, baseline systolic blood pressure, baseline diastolic blood pressure, body mass index, estimated glomerular filtration rate <60 mL/min per 1.73 m² or self-reported kidney disease, and history of diabetes. There were 10,707 participants contributing to all standard goal/placebo curves and 11,227 participants for the difference curves among those assigned low goal/active therapy and 11,228 participants for the standing SBP curves among those assigned log goal/active therapy. The hazard ratios are shown on a natural log scale. Included are kernel density plots, representing the distribution of change in SBP or standing SBP by treatment and by outcome status: low goal/active treatment, no outcome (blue, thick), low goal/active treatment outcome (blue, thin), standard goal/placebo, no outcome (red, thick), and standard goal/placebo, outcome (red, thin).




eFigure 7. Fully adjusted splines of difference in diastolic blood pressure or standing blood pressure

Adjusted hazard ratios by treatment status for change in diastolic blood pressure (DBP) with (**A**) cardiovascular disease or death or (**B**) all-cause mortality as well as for standing systolic blood pressure with (**C**) cardiovascular disease or death or (**D**) all-cause mortality, using a restricted cubic spline with 4 knots determined by Harrell's method. Figures are based on data from all nine trials. Shade represents 95% confidence intervals. Both models were expressed relative to the median value and were truncated at the 2.5^{th} and 97.5^{th} percentiles. Models were adjusted for age, sex, study, baseline systolic blood pressure, baseline diastolic blood pressure, body mass index, estimated glomerular filtration rate <60 mL/min per 1.73 m^2 or self-reported kidney disease, and history of diabetes. There were 10,707 participants contributing to all standard goal/placebo curves and 11,229 participants contributing to all low goal/active therapy curves. The hazard ratios are shown on a natural log scale. Included are kernel density plots, representing the distribution of change in DBP or standing DBP by treatment and by outcome status: low goal/active treatment, no outcome (blue, thick), low goal/active treatment outcome (blue, thin), standard goal/placebo, no outcome (red, thick), and standard goal/placebo, outcome (red, thin).




eFigure 8. Two-stage meta-analysis, orthostatic hypotension and cardiovascular disease or all-cause mortality


Two-stage meta-analysis examining the associations with cardiovascular disease or all-cause mortality of (A) orthostatic hypotension (OH, yes versus no), (B) a low or active treatment assignment (Low/Act) versus standard or placebo assignment (Std/Pla) among participants without OH, (C) Low/Act versus Std/Pla among participants with OH, and (D) the interaction between OH and treatment assignment. Individual effects were determined based on Cox models adjusted for age and sex. The pooled effect from the 9 trials were weighted with the inverse variance, using a random effects model.




eFigure 9. Two-stage meta-analysis, orthostatic hypotension and all-cause mortality

Two-stage meta-analysis examining the associations with all-cause mortality of (A) orthostatic hypotension (OH, yes versus no), (B) a low or active treatment assignment (Low/Act) versus standard or placebo assignment (Std/Pla) among participants without OH, (C) Low/Act versus Std/Pla among participants with OH, and (D) the interaction between OH and treatment assignment. Individual effects were determined based on Cox models adjusted for age and sex. The pooled effect from the 9 trials were weighted with the inverse variance, using a random effects model.






C. Low/Act vs Std/Pla among those with OH





D. Interaction of Assignment and OH




eFigure 10. Two-stage meta-analysis, standing hypotension and cardiovascular disease or all-cause mortality

Two-stage meta-analysis examining the associations with cardiovascular disease or all-cause mortality of (A) standing hypotension (HYP, yes versus no), (B) a low or active treatment assignment (Low/Act) versus standard or placebo assignment (Std/Pla) among participants without HYP, (C) Low/Act versus Std/Pla among participants with HYP, and (D) the interaction between HYP and treatment assignment. Individual effects were determined based on Cox models adjusted for age and sex. The pooled effect from the 9 trials were weighted with the inverse variance, using a random effects model.






C. Low/Act vs Std/Pla among those with HYP




D. Interaction of Assignment and HYP




D. LUW/ALL VS כונו/ רום מוווטווצ נווטצי שונווטעו הדר


eFigure 11. Two-stage meta-analysis, standing hypotension and all-cause mortality

Two-stage meta-analysis examining the associations with all-cause mortality of (**A**) standing hypotension (HYP, yes versus no), (**B**) a low or active treatment assignment (Low/Act) versus standard or placebo assignment (Std/Pla) among participants without HYP, (**C**) Low/Act versus Std/Pla among participants with HYP, and (**D**) the interaction between HYP and treatment assignment. Individual effects were determined based on Cox models adjusted for age and sex. The pooled effect from the 9 trials were weighted with the inverse variance, using a random effects model.






C. Low/Act vs Std/Pla among those with HYP



D. Interaction of Assignment and HYP



eTable 1. Comparison of covariate definitions across blood pressure treatment goal trials

	AASK	ACCORD BP	SPRINT	SPS3	UKPDS
Age	Reported Inclusion: 18-70 years	Reported Inclusion: 40-79 years	Reported <u>Inclusion:</u> ≥50 years	Reported Inclusion: ≥30 years	Reported Inclusion: 25-65 years
Female	Reported	Reported	Reported	Reported	Reported
Black	All participants (inclusion criterion)	Reported	Reported	Reported	Afro-Caribbean
BMI	Measured height and weight	Measured height and weight	Measured height and weight	Measured height and weight	Measured height and weight
CKD	Measured creatinine, CKD EPI equation, <60	Measured creatinine, CKD EPI equation eGFR <60 mL/min per 1.73 m ²	Measured creatinine, CKD EPI equation eGFR <60 mL/min per 1.73 m ²	Measured creatinine, CKD EPI equation eGFR <60 mL/min per 1.73 m ² ; Exclusion: Participants with an estimated	Measured creatinine, CKD EPI equation eGFR <60 mL/min per 1.73 m ² . Exclusion: serum creatinine
		1.75 111		GFR<40 mL/min per 1.73 m ²	concentration > 175 mmol/l
Diabetes	Baseline fasting glucose ≥ 126 mg/dL . AASK excluded adults with a fasting glucose ≥140 mg/dL or random glucose >200 mg/dL	Inclusion: 1. Type 2 diabetes mellitus defined according to the 1997 ADA criteria for 3 mo 2. An HbA1c level (obtained 3 mo before anticipated date of randomization) of a. 7.5%–11%: (i) If on insulin 1 U/kg and on 0 or 1 oral agent or (ii) If not on insulin, and on 0, 1, or 2 oral agents b. 7.5%–9%: (i) If on insulin 1 U/kg and on 2 oral agents, (ii) If on insulin 1 U/kg and on 2 oral agents, or (iii) If not on insulin and on 3 oral agents) Oral agents included: insulin secretagogues, biguanides, insulin enhancers	Exclusion: Participants taking medications for diabetes at any time in the last 12 months are excluded. Participants were also excluded if they had a fasting plasma glucose ≥126 mg/dL, A1C ≥6.5%, a 2-hour OGTT (2-h PG) ≥200 mg/dL or a random plasma glucose concentration ≥200 mg/dL.	Chronic elevation of fasting serum glucose, >120 mg/dL or chronic requirement for glucose lowering medications (insulin secretagogues, biguanides, insulin enhancers)	Inclusion: Newly diagnosed diabetes with fasting plasma glucose 6.1-15.0 mmol/l without diabetic symptoms <u>Exclusion:</u> Ketonuria >3 mmol/l Retinopathy requiring laser treatment

Stroke	Not reported at baseline	Not reported at baseline	Exclusion: History of stroke	Inclusion: A recent (within 180 days), symptomatic, MRI-confirmed lacunar stroke (>24 hours), and were without surgically amenable ipsilateral carotid artery stenosis or high-risk cardioembolic sources. Main exclusion criteria included disabling stroke (modified Rankin score of 4 or higher), previous intracranial hemorrhage from non-traumatic causes, retinal stroke, or cortical ischemic stroke	Self-reported
CVD	Not reported at baseline	History of CVD (prior MI, stroke, arterial revascularization, angina with ischemic changes on ECG at rest, changes on a graded exercise test, or positive cardiac imaging test results)	 Inclusion: Clinical CVD (other than stroke): a) Previous myocardial infarction, percutaneous coronary intervention, CABG, carotid endarterectomy (CE), carotid stenting b) Peripheral artery disease with revascularization c) Acute coronary syndrome with or without resting ECG change, ECG changes on a graded exercise test, or positive cardiac imaging study d) At least a 50% diameter stenosis of a coronary, carotid, or lower extremity artery e) Abdominal aortic aneurysm ≥5 cm with or without repair 	MI, angina, CHF, or revascularization procedure (e.g. CABG)	Self-reported history of stroke, MI, or heart failure

Abbreviations: ADA: American Diabetes Association; BMI: body mass index; CABG: coronary artery bypass graft; CHF: congestive heart failure; CKD: chronic kidney disease; CKD EPI: chronic kidney disease epidemiology collaboration; CVD: cardiovascular disease; ECG: electrocardiogram; eGFR: estimated glomerular filtration rate; ICD: international classification of disease; MRI: magnetic resonance imaging

Note this Table was adapted from Juraschek et al, Annals of Internal Medicine, 2020.

eTable 2. Comparison of covariate definitions across placebo-controlled trials

	HYVET	SHEP	SYST-EUR	TOMHS
		Calculated using difference of birthdate from		
	Reported	randomization visit	Reported	Reported
Age	Inclusion: ≥80 years	Inclusion: ≥60 years	Inclusion: ≥60 years	Inclusion: 45-69 years
Female	Reported	Reported	Reported	Reported
Black	Not Reported	Reported	Not Reported	Reported
BMI	Measured height and weight	Measured height and weight	Measured height and weight	Measured height and weight
	Measured creatinine, CKD EPI	Reported history of kidney disease or protein or blood in urine (Note: creatinine only		
СКД	equation eGFR <60 mL/min per 1.73 m ²	available in a subset of the population and thus was not used)	Measured creatinine, CKD EPI equation eGFR <60 mL/min per 1.73 m ²	Measured creatinine, CKD EPI equation eGFR <60 mL/min per 1.73 m ²
	Self-reported prevalent cases, antidiabetic treatment, or blood sugar >11.1 mmol/l	Reported history of non-insulin dependent diabetes		
	(irrespective of fasting or		Investigator reported diabetes or antidiabetic	
Diabetes	nonfasting)	Exclusion: Insulin dependent diabetes	drug intake	Fasting glucose ≥ 126 mg/dL
Stroke	Reported history of stroke	Reported history of stroke	History of stroke (ICD9 4300-4329, 4340-4349, 4360-4369)	Exclusion: Reported history of stroke
	Reported history of stroke, myocardial infarction, or heart		Reported history of stroke, myocardial infarction,	Exclusion: Reported history of
CVD	failure	Reported history of a heart attack	or heart failure	cardiovascular disease

Abbreviations: BMI: body mass index; CKD: chronic kidney disease; CKD EPI: chronic kidney disease epidemiology collaboration; CVD: cardiovascular disease; eGFR: estimated glomerular filtration rate; ICD: international classification of disease; MRI: magnetic resonance imaging

Note this Table was adapted from Juraschek et al, Annals of Internal Medicine, 2020.

eTable 3. Participant characteristics for all trials, trials of blood pressure treatment goal, and placebo-controlled trials

	All Trials, N=29,235	Treatment Goal Trials, N=15,198	Placebo-Controlled Trials, N=14,037
haracteristic	Mean (SD) or %	Mean (SD) or %	Mean (SD) or %
Demographic Information			
ge, years	69.0 (10.9) [N=29235]	64.8 (10.4) [N=15198]	73.5 (9.5) [N=14037]
ge >75 years, %	9057/29235 (31.0)	2696/15198 (17.7)	6361/14037 (45.3)
Vomen, %	14120/29235 (48.3)	5705/15198 (37.5)	8415/14037 (59.9)
Леп, %	15115/29235 (51.7)	9493/15198 (62.5)	5622/14037 (40.1)
lack*, %	5517/20702 (26.6)	4705/15198 (31.0)	812/5504 (14.8)
ast Medical Conditions			
Diabetes, %	4817/29231 (16.5)	3457/15196 (22.7)	1360/14035 (9.7)
rior stroke, %	2812/26818 (10.5)	2398/12783 (18.8)	414/14035 (2.9)
listory of CVD, %	3657/28134 (13.0)	2550/14109 (18.1)	1107/14025 (7.9)
lood Pressure Measures			
re-randomization seated SBP, mm Hg	155.1 (21.4) [N=29235]	141.6 (17.9) [N=15198]	169.8 (13.9) [N=14037]
re-randomization seated DBP, mm Hg	81.9 (11.6) [N=29235]	79.8 (12.6) [N=15198]	84.3 (9.9) [N=14037]
re-randomization standing SBP, mm Hg	153.0 (21.1) [N=29235]	142.1 (19.7) [N=15198]	164.9 (15.4) [N=14037]
re-randomization standing DBP, mm Hg	84.1 (12.0) [N=29235]	83.0 (13.4) [N=15198]	85.4 (10.1) [N=14037]
re-randomization postural change in SBP**, mm Hg	-2.1 (11.3) [N=29235]	0.5 (12.4) [N=15198]	-5.0 (9.3) [N=14037]
re-randomization postural change in DBP**, mm Hg	2.2 (7.4) [N=29235]	3.2 (7.8) [N=15198]	1.1 (6.8) [N=14037]
re-randomization seated BP ≥130/≥80 mm Hg, %	26288/29235 (89.9)	12260/15198 (80.7)	14028/14037 (99.9)
re-randomization OH, %	2592/29235 (8.9)	1310/15198 (8.6)	1282/14037 (9.1)
tanding SBP≤110 or DBP≤60 mm Hg pre-randomization, %	1307/29235 (4.5)	1094/15198 (7.2)	213/14037 (1.5)

Physical Measures & Laboratory Values

© 2023 American Medical Association. All rights reserved.

Body mass index, kg/m ²	28.4 (5.5) [N=29054]	30.0 (5.8) [N=15112]	26.7 (4.5) [N=13942]
Obese, %	9285/29054 (32.0)	6569/15112 (43.5)	2716/13942 (19.5)
eGFR***, mL/min per 1.73 m ²	70.0 (19.6) [N=23134]	72.7 (21.6) [N=13706]	66.1 (15.5) [N=9428]
Stage III CKD (eGFR < 60 mL/min per 1.73 m ²)***, %	8837/28719 (30.8)	4185/14811 (28.3)	4652/13908 (33.4)

For all trials, the N for the following characteristics was: 20,702 for Black race, 26,818 for prior stroke, 28,134 for history of cardiovascular disease, 29,054 for body mass index and obesity, 23,134 for eGFR, and 28,719 for stage 3 CKD.

Among the blood pressure treatment goal trials, the N for the following characteristics was: 15,196 for diabetes, 12,783 for prior stroke, 14,109 for history of cardiovascular disease, 15,112 for body mass index and obesity, 13,706 for eGFR, and 14,811 for stage 3 CKD.

Among the placebo-controlled trials, the N for the following characteristics was: 5,504 for Black race, 14,035 for diabetes, 14,035 for prior stroke, 14,025 for history of cardiovascular disease, 13,942 for body mass index and obesity, 9,428 for eGFR, and 13,908 for stage 3 CKD.

Abbreviations: BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure

*Self-reported

**Standing minus seated blood pressure. Note that since orthostatic hypotension is defined based on either systolic or diastolic thresholds, the means for systolic and diastolic blood pressure are less than the orthostatic hypotension threshold of -20 or -10 mm Hg.

***Based on the CKD EPI 2021 race-free, creatinine equation. eGFR was not available from UKPDS or SHEP. UKPDS provides stage III CKD categories based on the 2021 CKD-EPI race-free, creatinine equation. For SHEP we relied on a self-reported history of kidney disease.

eTable 4. Cross-tabulation of orthostatic hypotension and standing hypotension N=29,235

	No standing hypotension, N=27,928	Standing hypotension, N=1,307
No orthostatic hypotension, N=26,643	25,763	880
Orthostatic hypotension, N=2,592	2,165	427

		AASK		ACCORD		SPRINT		SPS3		UKPDS
Characteristic	Ν	Mean (SD) or %								
Demographic Information										
Age, years	1089	54.6 (10.7)	1321	62.0 (6.5)	9326	67.9 (9.4)	2345	62.9 (10.8)	1117	56.9 (8.1)
Age >75 years, %	1089	0	1321	4	9326	25	2345	14	1117	0
Women, %	1089	39	1321	46	9326	36	2345	37	1117	45
Men, %	1089	61	1321	54	9326	64	2345	64	1117	55
Black*, %	1089	100	1321	20	9326	32	2345	14	1117	8
Past Medical Conditions										
Diabetes, %	1089	7	1321	100	9324	2	2345	34	1117	100
Prior stroke, %	1089	NA	1321	NA	9321	1	2345	100	1117	0
History of CVD, %	1089	NA	1321	35	9326	20	2345	9	1117	1
Blood Pressure Measures										
Pre-randomization seated										
SBP, mm Hg	1089	143.9 (22.5)	1321	138.1 (16.3)	9326	139.7 (15.6)	2345	142.0 (18.4)	1117	158.6 (21.9)
Pre-randomization seated	1000		4004		0000		2245			
DBP, mm Hg Pre-randomization	1089	88.8 (13.5)	1321	76.2 (10.7)	9326	78.1 (11.9)	2345	77.9 (10.5)	1117	92.8 (11.2)
standing SBP, mm Hg	1089	143.2 (23.5)	1321	139.5 (16.9)	9326	140.3 (17.9)	2345	144.1 (22.3)	1117	155.2 (21.7)
Pre-randomization		(,						(,		
standing DBP, mm Hg	1089	91.6 (14.6)	1321	79.0 (11.2)	9326	81.8 (12.9)	2345	81.0 (12.8)	1117	93.8 (10.9)
Pre-randomization postural change in SBP**, mm Hg	1089	-0.6 (10.8)	1321	1.3 (13.0)	9326	0.6 (11.8)	2345	2.1 (14.0)	1117	-3.3 (13.1)
Pre-randomization postural	1005	0.0 (10.0)	1921	1.5 (15.6)	5520	0.0 (11.0)	2313	2.1 (1 1.0)	,	5.5 (15.1)
change in DBP**, mm Hg	1089	2.8 (8.2)	1321	2.9 (7.8)	9326	3.7 (7.5)	2345	3.1 (8.6)	1117	1.0 (7.3)
Pre-randomization seated										
BP ≥130/≥80 mm Hg, %	1089	86	1321	75	9326	80	2345	76	1117	98
Pre-randomization OH, %	1089	9	1321	8	9326	7	2345	10	1117	17

eTable 5. Baseline characteristics of each blood pressure treatment goal trial

Standing SBP≤110 or DBP≤60 mm Hg pre- randomization, %	1089	8	1321	7	9326	8	2345	8	1117	1
Physical Measures & Laboratory Values										
Body mass index, kg/m ²	1089	30.6 (6.6)	1321	32.5 (5.5)	9267	29.9 (5.8)	2340	28.8 (5.6)	1095	29.7 (5.5)
Obese, %	1089	47	1321	64	9267	43	2340	34	1095	40
eGFR***, mL/min per 1.73										
m ²	1087	42.4 (13.8)	1317	86.5 (16.8)	9287	72.4 (20.0)	2015	81.1 (18.8)	0	NA
Stage III CKD (eGFR < 60										
mL/min per 1.73 m ²)***, %	1087	90	1317	8	9287	27	2015	15	1105	26

Abbreviations: BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure

*Self-reported

**Standing minus seated blood pressure. Note that since orthostatic hypotension is defined based on either systolic or diastolic thresholds, the means for systolic and diastolic blood pressure are less than the orthostatic hypotension threshold of -20 or -10 mm Hg.

***Based on the CKD EPI 2021 race-free, creatinine equation. eGFR was not available from UKPDS. UKPDS provided stage III CKD categories based on the 2021 CKD-EPI race-free, creatinine equation.

eTable 6. Baseline characteristics of each placebo-controlled trial

		HYVET Mean (SD)		SHEP Mean (SD)		SYST-EUR Mean (SD) or		TOMHS Mean (SD)
Characteristic	Ν	or %	Ν	or %	Ν	%	Ν	or %
Demographic Information								
Age, years	3845	83.5 (3.2)	4602	72.1 (6.7)	4688	70.2 (6.7)	902	54.8 (6.4)
Age >75 years, %	3845	100	4602	33	4688	22	902	0
Nomen, %	3845	61	4602	57	4688	67	902	38
Men, %	3845	40	4602	43	4688	33	902	62
Black*, %	3845	NA	4602	14	4688	NA	902	20
Past Medical Conditions								
Diabetes, %	3845	10	4600	10	4688	10	902	6
Prior stroke, %	3845	7	4600	2	4688	1	902	0
History of CVD, %	3845	12	4590	9	4688	6	902	0
Blood Pressure Measures								
Pre-randomization seated SBP, mm Hg	2045		4602		4600	472 0 (44 0)	000	139.2
)re rendemization costed DBD mm llg	3845	173.5 (9.4)	4602	169.7 (11.6)	4688	172.8 (11.8)	902	(13.7)
Pre-randomization seated DBP, mm Hg	3845	90.8 (9.1)	4602	77.1 (9.2)	4688	84.9 (6.9)	902	89.7 (4.8) 137.9
Pre-randomization standing SBP, mm Hg	3845	167.9 (11.0)	4602	164.4 (14.7)	4688	168.0 (14.1)	902	(14.8)
Pre-randomization standing DBP, mm Hg	3845	88.7 (9.3)	4602	80.2 (10.6)	4688	86.9 (8.4)	902	90.1 (6.6)
Pre-randomization postural change in SBP**, mm Hg	3845	-5.5 (7.0)	4602	-5.4 (10.9)	4688	-4.8 (9.0)	902	-1.3 (9.6)
Pre-randomization postural change in DBP**, mm Hg	3845	-2.1 (5.2)	4602	3.1 (8.1)	4688	2.0 (5.7)	902	0.4 (5.5)
Pre-randomization seated BP ≥130/≥80 mm Hg, %	3845	100	4602	100	4688	100	902	99
Pre-randomization OH, %	3845	9	4602	12	4688	7	902	7
Standing SBP≤110 or DBP≤60 mm Hg pre-randomization, %	3845	1	4602	4	4688	0	902	2
Physical Measures & Laboratory Values								
Body mass index, kg/m ²	3837	24.7 (3.6)	4549	27.6 (5.1)	4654	27.0 (4.1)	902	28.9 (3.6)

© 2023 American Medical Association. All rights reserved.

Obese, %	3837	8	4549	26	4654	20	902	36
eGFR***, mL/min per 1.73 m ²	3845	64.9 (16.1)	0	NA	4681	66.0 (15.1)	902	72.2 (13.6)
Stage III CKD (eGFR < 60 mL/min per 1.73 m ²)***, %	3845	42	4480	25	4681	38	902	19

Abbreviations: BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure

*Self-reported

**Standing minus seated blood pressure. Note that since orthostatic hypotension is defined based on either systolic or diastolic thresholds, the means for systolic and diastolic blood pressure are less than the orthostatic hypotension threshold of -20 or -10 mm Hg.

***Based on the CKD EPI 2021 race-free, creatinine equation. eGFR was not available from SHEP. In SHEP, participants self-reported history of kidney disease.

eTable 7. Number of participants by distribution N=29,235

	Low/Active, no outcome	Low/Active, outcome	Standard/placebo, no outcome	Standard/placebo, outcome
Cardiovascular disea	se or all-cause mortality			
Change in SBP	Ν	Ν	Ν	Ν
≤-30	134	42	125	38
>-30 to ≤-20	613	114	513	128
>-20 to ≤-10	2223	366	1946	428
>-10 to <10	8210	1326	7523	1502
≥10 to <20	1295	240	1243	271
≥20 to <30	324	59	283	88
≥30	90	21	75	15
Standing SBP				
<110	217	54	183	70
110 to <130	1665	270	1507	295
130 to <150	3537	554	3148	608
150 to <170	4742	714	4375	888
≥170	2728	576	2495	609
Change in DBP				
≤-20	53	15	41	12
>-20 to ≤-10	457	109	429	128
>-10 to <10	10585	1697	9447	1921
≥10 to <20	1608	303	1617	363
≥20	186	44	174	46
Standing DBP				
<70	1333	266	1268	320
70 to <80	2771	428	2634	489
80 to <90	4313	622	3929	737
90 to <100	3462	529	2984	611
≥100	1010	323	893	313

All-cause mortality				
Change in SBP				
≤-30	144	32	136	27
>-30 to ≤-20	666	61	578	63
>-20 to ≤-10	2401	188	2171	203
>-10 to <10	8932	604	8352	673
≥10 to <20	1444	91	1426	88
≥20 to <30	361	22	337	34
≥30	99	12	83	7
Standing SBP				
<110	258	13	230	23
110 to <130	1856	79	1715	87
130 to <150	3879	212	3534	222
150 to <170	5092	364	4829	434
≥170	2962	342	2775	329
Change in DBP				
≤-20	59	9	45	8
>-20 to ≤-10	519	47	498	59
>-10 to <10	11464	818	10493	875
≥10 to <20	1799	112	1843	137
≥20	206	24	204	16
Standing DBP				
<70	1464	135	1438	150
70 to <80	3006	193	2909	214
80 to <90	4653	282	4340	326
90 to <100	3719	272	3300	295
≥100	1205	128	1096	110

© 2023 American Medical Association. All rights reserved.

Cardiovascular disease or all-cause mortality	Baseline Orthostatic Hypotension			
	Orthostatic hypotension, n/N	No orthostatic hypotension, n/N	HR (95% CI)	P
AASK	96/100	926/989	1.09 (0.89, 1.35)	0.41
ACCORD	15/101	130/1220	1.40 (0.82, 2.39)	0.22
SPRINT	93/683	881/8643	1.26 (1.01, 1.55)	0.04
SPS3	41/239	243/2106	1.55 (1.11, 2.16)	0.009
UKPDS	58/187	253/930	1.11 (0.84, 1.48)	0.46
Treatment Goal Trials	303/1310	2433/13888	1.24 (1.10, 1.40)	<0.001
HYVET	46/336	480/3509	0.99 (0.73, 1.35)	0.97
SHEP	102/554	765/4048	0.94 (0.76, 1.15)	0.55
SYST-EUR	45/333	413/4355	1.25 (0.92, 1.70)	0.15
TOMHS	5/59	46/843	1.57 (0.62, 3.95)	0.34
Placebo-controlled Trials	198/1282	1704/12755	1.00 (0.86, 1.16)	0.99
All Trials**	501/2592	4137/26643	1.14 (1.04, 1.26)	0.005

eTable 8. Association of baseline orthostatic hypotension with cardiovascular disease or all-cause mortality

All-Cause Mortality	Baseline Orthostatic Hypotension			
	Orthostatic	No orthostatic		
	hypotension, n/N	hypotension, n/N	HR (95% CI)	Ρ
AASK	12/100	94/989	1.32 (0.72, 2.40)	0.37
ACCORD	5/101	47/1220	1.29 (0.51, 3.24)	0.59
SPRINT	49/683	390/8643	1.41 (1.05, 1.90)	0.02
SPS3	21/239	105/2106	1.92 (1.20, 3.07)	0.007
UKPDS	42/187	172/930	1.18 (0.84, 1.66)	0.33
Treatment Goal Trials	129/1310	808/13888	1.39 (1.15, 1.68)	<0.001
HYVET	37/336	394/3509	0.97 (0.69, 1.36)	0.86
SHEP	66/554	377/4048	1.23 (0.94, 1.59)	0.13
SYST-EUR	28/333	257/4355	1.27 (0.86, 1.88)	0.23
томнѕ	1/59	8/843	1.76 (0.22,14.12)	0.59
Placebo-controlled Trials	132/1282	1036/12755	1.11 (0.93, 1.33)	0.25
All Trials***	261/2592	1844/26643	1.24 (1.09, 1.41)	0.001

Abbreviations: CI, confidence interval; HR, hazard ratio; n represents number of events; n/N represents number of events/number of participants at risk

Cox proportional hazards models adjusted for age, sex, and study (as a categorical variable).

There was no evidence for an interaction by treatment arm for individual studies or pooled study groupings with the exception of the SHEP trial for baseline orthostatic hypotension with respect to all-cause mortality (*P*-interaction = 0.032).

*Could not be calculated due to small numbers.

**Egger's test found no statistical evidence of bias (P > 0.05).

***Egger's test found no statistical evidence of bias (P > 0.05).

Cardiovascular disease or all-cause mortality	Baseline Standing Hypotension			
	Hypotension, n/N	No Hypotension, n/N	HR (95% CI)	Р
AASK	83/84	939/1005	1.37 (1.09, 1.72)	0.006
ACCORD	16/86	129/1235	1.61 (0.95, 2.72)	0.08
SPRINT	124/718	850/8608	1.49 (1.23, 1.80)	<0.001
SPS3	33/191	251/2154	1.51 (1.05, 2.17)	0.03
UKPDS	3/15	308/1102	0.68 (0.22, 2.13)	0.51
Treatment Goal Trials	259/1094	2477/14104	1.50 (1.32, 1.71)	<0.001
HYVET	3/22	523/3823	1.04 (0.34, 3.25)	0.94
SHEP	37/162	830/4440	1.16 (0.83, 1.61)	0.39
SYST-EUR	5/15	453/4673	1.21 (0.50, 2.98)	0.67
TOMHS	0/14	51/888	*	*
Placebo-controlled Trials	45/213	1857/13824	1.11 (0.83, 1.50)	0.48
All Trials**	304/1307	4334/27928	1.39 (1.24, 1.57)	<0.001

eTable 9. Association of baseline standing hypotension with cardiovascular disease or all-cause mortality

All-Cause Mortality		Baseline Standing Hypotension				
	Hypotension, n/N	No Hypotension, n/N	HR (95% CI)	Р		
AASK	9/84	97/1005	1.24 (0.63, 2.47)	0.53		
ACCORD	5/86	47/1235	1.24 (0.49, 3.15)	0.64		
SPRINT	62/718	377/8608	1.50 (1.14, 1.97)	0.004		
SPS3	18/191	108/2154	1.73 (1.05, 2.86)	0.03		
UKPDS	2/15	212/1102	0.70 (0.17, 2.83)	0.62		
Treatment Goal Trials	96/1094	841/14104	1.50 (1.21, 1.85)	<0.001		
HYVET	3/22	428/3823	1.30 (0.42, 4.06)	0.65		
SHEP	20/162	423/4440	1.13 (0.72, 1.77)	0.60		
SYST-EUR	4/15	281/4673	1.13 (0.41, 3.09)	0.81		
томнѕ	0/14	9/888	*	*		
Placebo-controlled Trials	27/213	1141/13824	1.17 (0.79, 1.72)	0.43		
All Trials***	123/1307	1982/27928	1.38 (1.14, 1.66)	<0.0001		

Abbreviations: CVD, cardiovascular disease; CI, confidence interval; HR, hazard ratio; n represents number of events; N represents overall number of participants.

Cox proportional hazards models adjusted for age, sex, and study (as a categorical variable).

There was no evidence for an interaction by treatment arm for individual studies or pooled study groupings.

*Could not be calculated due to small numbers.

**Egger's test found no statistical evidence of bias (*P* > 0.05).

***Egger's test found no statistical evidence of bias (P > 0.05).

Cardiovascular disease or all-cause mortality	Baseline Orthostatic Hypotension			
	Orthostatic	No orthostatic		
	hypotension, n/N	hypotension, n/N	HR (95% CI)	Р
AASK	96/100	924/987	1.09 (0.88, 1.34)	0.44
ACCORD	15/101	129/1216	1.29 (0.75, 2.25)	0.36
SPRINT	91/675	874/8553	1.16 (0.93, 1.45)	0.18
SPS3	35/199	227/1811	1.32 (0.92, 1.89)	0.14
UKPDS	54/178	247/905	0.95 (0.70, 1.29)	0.72
Treatment Goal Trials	291/1253	2401/13472	1.18 (1.04, 1.33)	0.01
HYVET	46/336	479/3501	0.99 (0.73, 1.34)	0.94
SHEP	96/533	724/3894	0.92 (0.74, 1.13)	0.42
SYST-EUR	45/331	402/4316	1.20 (0.88, 1.64)	0.25
TOMHS	5/59	46/843	1.45 (0.57, 3.69)	0.43
Placebo-controlled Trials	192/1259	1651/12554	0.99 (0.85, 1.15)	0.88
All Trials	483/2512	4052/26026	1.11 (1.01, 1.22)	0.04

eTable 10. Association of baseline orthostatic hypotension with cardiovascular disease or all-cause mortality adjusted for additional cardiovascular risk factors

All-Cause Mortality	Ba	Baseline Orthostatic Hypotension			
	Orthostatic	No orthostatic			
	hypotension, n/N	hypotension, n/N	HR (95% CI)	Ρ	
AASK	12/100	94/987	1.32 (0.72, 2.41)	0.37	
ACCORD	5/101	47/1216	1.25 (0.48, 3.23)	0.65	
SPRINT	47/675	385/8553	1.23 (0.90, 1.67)	0.19	
SPS3	18/199	97/1811	1.60 (0.96, 2.66)	0.07	
UKPDS	41/178	168/905	1.06 (0.74, 1.51)	0.77	
Treatment Goal Trials	123/1253	791/13472	1.25 (1.03, 1.52)	0.02	
HYVET	37/336	393/3501	0.95 (0.68, 1.34)	0.77	
SHEP	63/533	353/3894	1.23 (0.94, 1.61)	0.14	
SYST-EUR	28/331	248/4316	1.15 (0.77, 1.72)	0.49	
томнѕ	1/59	8/843	1.91 (0.23,15.61)	0.54	
Placebo-controlled Trials	129/1259	1002/12554	1.10 (0.91, 1.33)	0.31	
All Trials	252/2512	1793/26026	1.18 (1.03, 1.35)	0.02	

Abbreviations: CI, confidence interval; HR, hazard ratio; n represents number of events; n/N represents number of events/number of participants at risk

Cox proportional hazards models adjusted for age, sex, seated systolic blood pressure, seated diastolic blood pressure, eGFR<60 mL/min per 1.73 m², body mass index, and diabetes status

Pooled estimates were additionally adjusted for study (as a categorical variable).

There was no evidence for an interaction by treatment arm for individual studies or pooled study groupings.

Cardiovasculard disease or all-cause mortality	Baseline Standing Hypotension			
	Hypotension, n/N	No Hypotension, n/N	HR (95% CI)	Р
AASK	83/84	937/1003	1.53 (1.20, 1.97)	<0.001
ACCORD	16/86	128/1231	1.67 (0.94, 2.95)	0.08
SPRINT	124/713	841/8515	1.53 (1.24, 1.89)	<0.001
SPS3	28/162	234/1848	1.53 (1.00, 2.35)	0.05
UKPDS	3/15	298/1068	1.10 (0.34, 3.51)	0.88
Treatment Goal Trials	254/1060	2438/13665	1.63 (1.41, 1.88)	<0.001
HYVET	3/22	522/3815	2.34 (0.72, 7.57)	0.16
SHEP	37/160	783/4267	1.09 (0.76, 1.56)	0.64
SYST-EUR	5/15	442/4632	1.14 (0.45, 2.92)	0.78
TOMHS	0/14	51/888	*	*
Placebo-controlled Trials	45/211	1798/13602	1.28 (0.94, 1.76)	0.12
All Trials	299/1271	4236/27267	1.55 (1.36, 1.76)	<0.001
All-Cause Mortality	Basel	ine Standing Hypotension		
	Hypotension, n/N	No Hypotension, n/N	HR (95% CI)	Ρ
AASK	9/84	97/1003	1.55 (0.72 <i>,</i> 3.30)	0.26
ACCORD	5/86	47/1231	1.02 (0.38, 2.78)	0.96
SPRINT	62/713	370/8515	1.67 (1.23, 2.26)	0.001
SPS3	15/162	100/1848	2.27 (1.24, 4.16)	0.01
UKPDS	2/15	207/1068	1.18 (0.28, 4.90)	0.82
Treatment Goal Trials	93/1060	821/13665	1.71 (1.35, 2.17)	0.008

3/22

20/160

4/15

427/3815

396/4267

272/4632

2.83 (0.87, 9.25)

0.98 (0.60, 1.60)

1.19 (0.41, 3.46)

0.08

0.93

0.75

eTable 11. Association of baseline standing hypotension with cardiovascular disease or all-cause mortality adjusted for additional cardiovascular risk factors

HYVET

SYST-EUR

SHEP

томнѕ	0/14	9/888	*	*
Placebo-controlled Trials	27/211	1104/13602	1.38 (0.92, 2.08)	0.12
All Trials	120/1271	1925/27267	1.61 (1.31, 1.98)	<0.001

Abbreviations: CVD, cardiovascular disease; CI, confidence interval; HR, hazard ratio; n represents number of events; N represents overall number of participants.

Cox proportional hazards models adjusted for age, sex, seated systolic blood pressure, seated diastolic blood pressure, eGFR<60 mL/min per 1.73 m², body mass index, and diabetes status

Pooled estimates were additionally adjusted for study (as a categorical variable).

There was no evidence for an interaction by treatment arm for individual studies or pooled study groupings.

*Could not be calculated due to small numbers.

Cardiovascular disease or all-cause								
mortality	Bas	seline Orthostatic Hy	potension			Baseline Standing	Hypotension	
·	Orthostatic hypotension, n/N	No orthostatic hypotension, n/N	HR (95% CI)	Р	Hypotension, n/N	No Hypotension, n/N	HR (95% CI)	Р
AASK	45/47	457/491	1.09 (0.80, 1.48)	0.58	37/38	465/500	1.23 (0.88, 1.73)	0.23
ACCORD	6/56	59/602	1.13 (0.49, 2.63)	0.77	8/49	57/609	1.57 (0.74, 3.30)	0.24
SPRINT	40/344	396/4319	1.20 (0.87, 1.66)	0.28	59/361	377/4302	1.59 (1.20, 2.10)	0.001
SPS3	19/114	110/1043	1.81 (1.11, 2.96)	0.02	17/94	112/1063	1.86 (1.12, 3.11)	0.02
UKPDS	39/126	149/615	1.24 (0.87, 1.76)	0.24	2/7	186/734	1.11 (0.28, 4.50)	0.88
Treatment Goal Trials	149/687	1171/7070	1.24 (1.05, 1.47)	0.01	123/549	1197/7208	1.58 (1.31, 1.90)	<0.001
HYVET	14/153	209/1780	0.77 (0.45, 1.32)	0.33	2/10	221/1923	1.92 (0.48, 7.74)	0.36
SHEP	51/279	333/2029	1.15 (0.86, 1.55)	0.34	18/76	366/2232	1.40 (0.87, 2.25) 3.67	0.17
SYST-EUR	21/180	186/2211	1.25 (0.80, 1.96)	0.33	1/7	206/2384	(0.51,26.40)	0.20
TOMHS Placebo-controlled	3/47	31/621	1.31 (0.40, 4.29)	0.65	0/12	34/656	*	*
Trials	89/659	759/6641	1.06 (0.85, 1.32)	0.63	21/105	827/7195	1.30 (0.84, 2.01)	0.25
All Trials**	238/1346	1930/13711	1.17 (1.02, 1.34)	0.02	144/654	2024/14403	1.49 (1.25, 1.77)	<0.001
	-							

eTable 12. Association between orthostatic or standing hypotension and outcomes among those assigned a more intensive blood pressure goal or active treatment

All-Cause Mortality	Bas	eline Orthostatic Hy	potension		Baseline Standing Hypotension						
	Orthostatic hypotension, n/N	No orthostatic hypotension, n/N	HR (95% CI)	P	Hypotension, n/N	No Hypotension, n/N	HR (95% CI)	Р			
AASK	4/47	41/491	1.06 (0.38, 2.96)	0.92	2/38	43/500	0.71 (0.17, 2.93)	0.63			
-	•	•				•					
ACCORD	3/56	24/602	1.30 (0.38, 4.38)	0.68	4/49	23/609	1.67 (0.57 <i>,</i> 4.94)	0.35			
SPRINT	20/344	175/4319	1.26 (0.79, 2.01)	0.33	30/361	165/4302	1.63 (1.10, 2.42)	0.02			
SPS3	11/114	49/1043	2.55 (1.32, 4.92)	0.005	7/94	53/1063	1.43 (0.65, 3.14)	0.38			
UKPDS	28/126	106/615	1.24 (0.82, 1.88)	0.32	1/7	133/734	0.80 (0.11, 5.74)	0.82			

Treatment Goal Trials	66/687	395/7070	1.38 (1.06, 1.80)	0.02	44/549	417/7208	1.54 (1.12, 2.12)	0.008
HYVET	14/153	182/1780	0.89 (0.52, 1.53)	0.67	2/10	194/1923	2.24 (0.56, 9.05)	0.26
SHEP	37/279	173/2029	1.62 (1.14, 2.32)	0.008	9/76	201/2232	1.15 (0.59, 2.24)	0.69
SYST-EUR	11/180	126/2211	0.98 (0.53, 1.82)	0.95	1/7	136/2384	8.91 (1.22,65.16)	0.03
TOMHS	1/47	5/621	2.73 (0.32,23.36)	0.36	0/12	6/656	*	*
Placebo-controlled Trials	63/659	486/6641	1.20 (0.92, 1.56)	0.17	12/105	537/7195	1.25 (0.70, 2.23)	0.45
All Trials***	129/1346	881/13711	1.29 (1.07, 1.55)	0.008	56/654	954/14403	1.41 (1.07, 1.87)	0.01

Abbreviations: CI, confidence interval; HR, hazard ratio; n represents number of events; N represents overall number of participant at risk.

Cox proportional hazards models adjusted for age, sex, and study.

Pooled estimates were additionally adjusted for study (as a categorical variable).

*Could not be calculated due to small numbers.

Cardiovascular disease								
or all-cause mortality	В	aseline Orthostatic H	ypotension			Baseline Standing	Hypotension	
	Orthostatic	No orthostatic			Hypotension,	No Hypotension,		
	hypotension, n/N	hypotension, n/N	HR (95% CI)	Р	n/N	n/N	HR (95% CI)	Р
AASK	51/53	469/498	1.10 (0.82, 1.47)	0.53	46/46	474/505	1.50 (1.11, 2.03)	0.009
ACCORD	9/45	71/618	1.69 (0.84, 3.39)	0.14	8/37	72/626	1.72 (0.82, 3.61)	0.15
SPRINT	53/339	485/4324	1.31 (0.98, 1.74)	0.07	65/357	473/4306	1.41 (1.09, 1.84)	0.01
SPS3	22/125	133/1063	1.37 (0.87, 2.15)	0.17	16/97	139/1091	1.26 (0.75, 2.12)	0.39
UKPDS	19/61	104/315	0.95 (0.58, 1.55)	0.82	1/8	122/368	0.35 (0.05, 2.54)	0.30
Treatment Goal Trials	154/623	1262/6818	1.25 (1.05, 1.48)	0.01	136/545	1280/6896	1.43 (1.20, 1.71)	<0.001
HYVET	32/183	271/1729	1.12 (0.78, 1.62)	0.54	1/12	302/1900	0.53 (0.07, 3.78)	0.53
SHEP	51/275	432/2019	0.78 (0.58, 1.04)	0.09	19/86	464/2208	0.98 (0.62, 1.56)	0.94
SYST-EUR	24/153	227/2144	1.27 (0.83, 1.93)	0.27	4/8	247/2289	1.15 (0.41, 3.18)	0.79
TOMHS	2/12	15/222	2.70 (0.60,12.13)	0.20	0/2	17/232	*	*
Placebo-controlled Trials	109/623	945/6114	0.95 (0.78, 1.16)	0.62	24/108	1030/6629	0.98 (0.65, 1.48)	0.93
All Trials**	263/1246	2207/12932	1.12 (0.98, 1.27)	0.09	160/653	2310/13525	1.31 (1.11, 1.54)	0.001
All-Cause Mortality	В	aseline Orthostatic H	vnotension			Baseline Standing	Hypotension	

eTable 13. Association between orthostatic or standing hypotension and outcomes among those assigned a standard blood pressure goal or placebo

All-Cause Mortality	Ba	aseline Orthostatic Hy	potension		Baseline Standing Hypotension					
	Orthostatic	No orthostatic	HR (95% CI)	Р	Hypotension,	No Hypotension,	HR (95% CI)	Р		
	hypotension, n/N	hypotension, n/N	• •	-	n/N	n/N	· · ·	-	I	
AASK	8/53	53/498	1.48 (0.70, 3.11)	0.30	7/46	54/505	1.52 (0.69, 3.35)	0.30		
ACCORD	2/45	23/618	1.04 (0.24, 4.41)	0.96	1/37	24/626	0.53 (0.07, 3.98)	0.54		
SPRINT	29/339	215/4324	1.54 (1.04, 2.27)	0.03	32/357	212/4306	1.39 (0.96, 2.03)	0.08		
SPS3	10/125	56/1063	1.51 (0.77, 2.96)	0.23	11/97	55/1091	1.99 (1.03, 3.81)	0.04		
UKPDS	14/61	66/315	1.09 (0.61, 1.96)	0.76	1/8	79/368	0.60 (0.08, 4.30)	0.61		
Treatment Goal Trials	63/623	413/6818	1.40 (1.07, 1.83)	0.01	52/545	424/6896	1.45 (1.08, 1.94)	0.01		
HYVET	23/183	212/1729	1.01 (0.66, 1.56)	0.96	1/12	234/1900	0.69 (0.10, 4.90)	0.71		

TOMHS	0/12	3/222	*	*	0/2	3/232	*	*
Placebo-controlled Trials	69/623	550/6114	1.04 (0.81, 1.33)	0.78	15/108	604/6629	1.12 (0.66, 1.87)	0.68
_All Trials***	132/1246	963/12932	1.19 (0.99, 1.43)	0.06	67/653	1028/13525	1.34 (1.04, 1.72)	0.02

Abbreviations: CI, confidence interval; HR, hazard ratio; n represents number of events; N represents overall number of participants at risk.

Cox proportional hazards models adjusted for age, sex, and study.

Pooled estimates were additionally adjusted for study (as a categorical variable).

*Could not be calculated due to small numbers.

eTable 14. Treatment effects on cardiovascular disease or all-cause mortality by baseline orthostatic hypotension, unadjusted

Orthostatic Hypotension

Cardiovascular Disease or All-cause Mortality

	,		Orthostatic Hypotension			No Orthostatic Hypotension	
							P-
	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	interaction
AASK	45/47	51/53	0.95 (0.63, 1.43)	457/491	469/498	0.96 (0.84, 1.09)	0.97
ACCORD	6/56	9/45	0.48 (0.17, 1.35)	59/602	71/618	0.86 (0.61, 1.21)	0.31
SPRINT	40/344	53/339	0.74 (0.49, 1.11)	396/4319	485/4324	0.81 (0.71, 0.92)	0.68
SPS3	19/114	22/125	1.08 (0.58, 1.99)	110/1043	133/1063	0.81 (0.63, 1.04)	0.41
UKPDS	39/126	19/61	0.96 (0.55, 1.65)	149/615	104/315	0.71 (0.55, 0.92)	0.35
Treatment Goal Trials	149/687	154/623	0.77 (0.62, 0.97)	1171/7070	1262/6818	0.80 (0.74, 0.87)	0.55
HYVET	14/153	32/183	0.50 (0.27, 0.93)	209/1780	271/1729	0.75 (0.62, 0.89)	0.22
SHEP	51/279	51/275	1.06 (0.72, 1.57)	333/2029	432/2019	0.73 (0.64, 0.85)	0.11
SYST-EUR	21/180	24/153	0.75 (0.42, 1.36)	186/2211	227/2144	0.77 (0.64, 0.94)	0.94
томня	3/47	2/12	0.35 (0.06, 2.10)	31/621	15/222	0.73 (0.39, 1.35)	0.42
Placebo-Controlled							
Trials	89/659	109/623	0.78 (0.59, 1.03)	759/6641	945/6114	0.71 (0.65, 0.78)	0.59
All Trials	238/1346	263/1246	0.80 (0.67, 0.95)	1930/13711	2207/12932	0.78 (0.73, 0.83)	0.87
All-cause Mortality							
			Orthostatic Hypotension			No Orthostatic Hypotension	
	··· / N1 / 1 ···· / A · +)			··· (N) (1 ····· (A ···)			<i>P</i> -
A A C //	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	interaction
AASK	4/47	8/53	0.52 (0.16, 1.74)	41/491	53/498	0.75 (0.50, 1.13)	0.59
ACCORD	3/56	2/45	1.22 (0.20, 7.34)	24/602	23/618	1.09 (0.61, 1.93)	0.94
SPRINT	20/344	29/339	0.67 (0.38, 1.18)	175/4319	215/4324	0.81 (0.66, 0.99)	0.53
SPS3	11/114	10/125	1.43 (0.61, 3.37)	49/1043	56/1063	0.85 (0.58, 1.25)	0.28
UKPDS	28/126	14/61	0.93 (0.49, 1.76)	106/615	66/315	0.83 (0.61, 1.13)	0.73

Treatment Goal Trials	66/687	63/623	0.83 (0.59, 1.18)	395/7070	413/6818	0.84 (0.73, 0.96)	0.85
HYVET	14/153	23/183	0.71 (0.37, 1.38)	182/1780	212/1729	0.84 (0.69, 1.02)	0.64
SHEP	37/279	29/275	1.40 (0.86, 2.28)	173/2029	204/2019	0.83 (0.68, 1.02)	0.06
SYST-EUR	11/180	17/153	0.55 (0.26, 1.18)	126/2211	131/2144	0.93 (0.73, 1.19)	0.21
томня	1/47	0/12	*	5/621	3/222	0.59 (0.14, 2.48)	*
Placebo-Controlled							
Trials	63/659	69/623	0.89 (0.63, 1.26)	486/6641	550/6114	0.80 (0.71, 0.90)	0.57
All Trials	129/1346	132/1246	0.87 (0.68, 1.11)	881/13711	963/12932	0.82 (0.75, 0.90)	0.76

All models were unadjusted.

*Could not be calculated due to small numbers.

Cardiovascular Disease or All-	-cause Mortality						
			Hypotension			No Hypotension	
	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	P -interaction
AASK	37/38	46/46	0.82 (0.53, 1.27)	465/500	474/505	0.97 (0.86, 1.11)	0.46
ACCORD	8/49	8/37	0.72 (0.27, 1.91)	57/609	72/626	0.81 (0.57, 1.15)	0.81
SPRINT	59/361	65/357	0.89 (0.62, 1.26)	377/4302	473/4306	0.79 (0.69, 0.90)	0.55
SPS3	17/94	16/97	1.18 (0.59, 2.33)	112/1063	139/1091	0.80 (0.62, 1.02)	0.29
UKPDS	2/7	1/8	2.20 (0.20,24.33)	186/734	122/368	0.74 (0.59, 0.93)	0.29
Treatment Goal Trials	123/549	136/545	0.89 (0.70, 1.14)	1197/7208	1280/6896	0.79 (0.73, 0.86)	0.35
HYVET	2/10	1/12	2.35 (0.21,25.89)	221/1923	302/1900	0.72 (0.60, 0.85)	0.31
SHEP	18/76	19/86	1.04 (0.55, 1.99)	366/2232	464/2208	0.75 (0.66, 0.86)	0.33
SYST-EUR	1/7	4/8	0.29 (0.03, 2.65)	206/2384	247/2289	0.78 (0.65, 0.94)	0.43
TOMHS Placebo-Controlled	0/12	0/2	*	34/656	17/232	0.69 (0.39, 1.24)	*
Trials	21/105	24/108	0.89 (0.50, 1.61)	827/7195	1030/6629	0.72 (0.65, 0.78)	0.43
All Trials*	144/654	160/653	0.89 (0.71, 1.12)	2024/14403	2310/13525	0.77 (0.73, 0.82)	0.27
All-cause Mortality							
			Hypotension			No Hypotension	
	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	P -interaction
AASK	2/38	7/46	0.32 (0.07, 1.53)	43/500	54/505	0.78 (0.52, 1.16)	0.29
ACCORD	4/49	1/37	2.64 (0.29,23.95)	23/609	24/626	1.00 (0.56, 1.77)	0.36
SPRINT	30/361	32/357	0.92 (0.56, 1.52)	165/4302	212/4306	0.78 (0.63, 0.95)	0.54
SPS3	7/94	11/97	0.65 (0.25, 1.69)	53/1063	55/1091	0.96 (0.66, 1.40)	0.46
UKPDS	1/7	1/8	1.07 (0.07,17.12)	133/734	79/368	0.84 (0.64, 1.11)	0.72
Treatment Goal Trials	44/549	52/545	0.83 (0.56, 1.24)	417/7208	424/6896	0.84 (0.73, 0.96)	0.99
HYVET	2/10	1/12	2.35 (0.21,25.89)	194/1923	234/1900	0.82 (0.68, 0.99)	0.37
SHEP	9/76	11/86	0.95 (0.39, 2.30)	201/2232	222/2208	0.89 (0.74, 1.08)	0.92

eTable 15. Treatment effects on cardiovascular disease or all-cause mortality by baseline standing hypotension, unadjusted

All Trials**	56/654	67/653	0.83 (0.58, 1.19)	954/14403	1028/13525	0.83 (0.76, 0.90)	0.87
Trials	12/105	15/108	0.84 (0.40, 1.81)	537/7195	604/6629	0.81 (0.72, 0.91)	0.87
TOMHS Placebo-Controlled	0/12	0/2	*	6/656	3/232	0.70 (0.18, 2.81)	*
SYST-EUR	1/7	3/8	0.45 (0.05, 4.35)	136/2384	145/2289	0.90 (0.71, 1.14)	0.52

Standing hypotension defined as SBP≤110 mm Hg or DBP≤60 mm Hg

All models were unadjusted.

eTable 16. Treatment effects on cardiovascular disease or all-cause mortality by baseline orthostatic hypotension, adjusted for additional cardiovascular risk factors

Orthostatic Hypotension

Cardiovascular Disease or All-cause Mortality

			Orthostatic Hypotension			No Orthostatic Hypotension	
	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	P -interaction
AASK	45/47	51/53	0.92 (0.59, 1.44)	455/489	469/498	0.96 (0.84, 1.09)	0.89
ACCORD	6/56	9/45	0.47 (0.17, 1.36)	59/601	70/615	0.89 (0.63, 1.26)	0.31
SPRINT	40/343	51/332	0.78 (0.51, 1.18)	392/4279	482/4274	0.79 (0.70, 0.91)	0.93
SPS3	16/89	19/110	1.25 (0.64, 2.45)	103/897	124/914	0.80 (0.62, 1.04)	0.24
UKPDS	37/119	17/59	0.94 (0.52 <i>,</i> 1.69)	146/600	101/305	0.73 (0.56, 0.94)	0.48
Treatment Goal							
Trials	144/654	147/599	0.88 (0.70, 1.11)	1155/6866	1246/6606	0.85 (0.79, 0.92)	0.79
		_					
HYVET	14/153	32/183	0.48 (0.25, 0.90)	208/1776	271/1725	0.75 (0.62, 0.90)	0.21
SHEP	49/268	47/265	1.15 (0.77, 1.73)	307/1940	417/1954	0.68 (0.59, 0.79)	0.02
SYST-EUR	21/178	24/153	0.74 (0.41, 1.33)	181/2190	221/2126	0.74 (0.61, 0.90)	0.97
TOMHS	3/47	2/12	0.32 (0.04, 2.37)	31/621	15/222	0.73 (0.40, 1.36)	0.54
Placebo-Controlled							
Trials	87/646	105/613	0.81 (0.61, 1.08)	727/6527	924/6027	0.72 (0.65, 0.79)	0.38
All Trials	231/1300	252/1212	0.85 (0.71, 1.02)	1882/13393	2170/12633	0.80 (0.75, 0.85)	0.52
All-cause Mortality							
			Orthostatic			No Orthostatic	
			Hypotension			Hypotension	
	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	P -interaction
AASK	4/47	8/53	0.34 (0.09, 1.27)	41/489	53/498	0.75 (0.49, 1.12)	0.50
ACCORD	3/56	2/45	0.73 (0.10, 5.20)	24/601	23/615	1.12 (0.63, 1.99)	0.99
SPRINT	20/343	27/332	0.75 (0.42, 1.34)	172/4279	213/4274	0.80 (0.66, 0.98)	0.81
SPS3	9/89	9/110	1.54 (0.58, 4.08)	47/897	50/914	0.88 (0.59, 1.31)	0.23
UKPDS	27/119	14/59	0.89 (0.46, 1.72)	103/600	65/305	0.83 (0.60, 1.13)	0.93

Treatment Goal							
Trials	63/654	60/599	0.85 (0.59, 1.23)	387/6866	404/6606	0.84 (0.73, 0.96)	0.99
HYVET	14/153	23/183	0.70 (0.36, 1.37)	181/1776	212/1725	0.84 (0.69, 1.02)	0.65
SHEP	36/268	27/265	1.54 (0.93, 2.56)	159/1940	194/1954	0.79 (0.64, 0.97)	0.02
SYST-EUR	11/178	17/153	0.57 (0.26, 1.24)	121/2190	127/2126	0.86 (0.67, 1.11)	0.32
TOMHS	1/47	0/12	*	5/621	3/222	0.60 (0.14, 2.56)	*
Placebo-Controlled							
Trials	62/646	67/613	0.96 (0.68, 1.36)	466/6527	536/6027	0.82 (0.72, 0.93)	0.35
All Trials	125/1300	127/1212	0.91 (0.71, 1.17)	853/13393	940/12633	0.83 (0.76, 0.91)	0.52

*Could not be calculated due to small numbers.

Cox proportional hazards models adjusted for age, sex, seated systolic blood pressure, seated diastolic blood pressure, eGFR<60 mL/min per 1.73 m², body mass index, and diabetes status. Pooled estimates are additionally adjusted for study.

Cardiovascular Disease or All	-cause Mortality						
			Hypotension			No Hypotension	
	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	P -interaction
AASK	37/38	46/46	0.91 (0.57, 1.46)	463/498	474/505	0.97 (0.86, 1.11)	0.45
ACCORD	8/49	8/37	0.67 (0.25, 1.86)	57/608	71/623	0.84 (0.59, 1.19)	0.95
SPRINT	59/360	65/353	0.86 (0.60, 1.22)	373/4262	468/4253	0.78 (0.68, 0.90)	0.65
SPS3	16/78	12/84	1.26 (0.59, 2.71)	103/908	131/940	0.79 (0.61, 1.03)	0.13
UKPDS	2/7	1/8	*	181/712	117/356	0.75 (0.60, 0.95)	0.42
Treatment Goal Trials	122/532	132/528	0.95 (0.74, 1.22)	1177/6988	1261/6677	0.85 (0.78, 0.92)	0.43
HYVET	2/10	1/12	97.19 (0.02 <i>,</i> 4.4e+05)	220/1919	302/1896	0.72 (0.60, 0.85)	0.37
SHEP	18/76	19/84	1.07 (0.55, 2.08)	338/2132	445/2135	0.71 (0.62, 0.82)	0.36
SYST-EUR	1/7	4/8	*	201/2361	241/2271	0.74 (0.61, 0.89)	0.53
томня	0/12	0/2	*	34/656	17/232	0.70 (0.39, 1.25)	*
Placebo-Controlled							
Trials	21/105	24/106	0.99 (0.55, 1.80)	793/7068	1005/6534	0.72 (0.66, 0.80)	0.42
All Trials*	143/637	156/634	0.94 (0.75, 1.18)	1970/14056	2266/13211	0.79 (0.75, 0.84)	0.14
All-cause Mortality							
			Hypotension			No Hypotension	
	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	P -interaction
AASK	2/38	7/46	0.36 (0.05, 2.72)	43/498	54/505	0.75 (0.50, 1.12)	0.44
ACCORD	4/49	1/37	2.35 (0.23,23.71)	23/608	24/623	1.05 (0.59, 1.86)	0.35
SPRINT	30/360	32/353	0.92 (0.56, 1.51)	162/4262	208/4253	0.78 (0.63, 0.96)	0.61
SPS3	6/78	9/84	0.45 (0.15, 1.36)	50/908	50/940	0.98 (0.66, 1.45)	0.42
UKPDS	1/7	1/8	*	129/712	78/356	0.83 (0.63, 1.11)	0.91
Treatment Goal Trials	43/532	50/528	0.85 (0.57, 1.29)	407/6988	414/6677	0.84 (0.73, 0.96)	0.96
HYVET	2/10	1/12	97.19 (0.02 <i>,</i> 4.4e+05)	193/1919	234/1896	0.82 (0.68, 1.00)	0.42
SHEP	9/76	11/84	0.85 (0.35, 2.07)	186/2132	210/2135	0.87 (0.72, 1.06)	0.93

eTable 17. Treatment effects on cardiovascular disease or all-cause mortality by baseline standing hypotension, adjusted for additional cardiovascular risk factors

All Trials**	55/637	65/634	0.83 (0.58, 1.19)	923/14056	1002/13211	0.84 (0.77, 0.92)	0.88
Placebo-Controlled Trials	12/105	15/106	0.93 (0.43, 2.02)	516/7068	588/6534	0.84 (0.74, 0.94)	0.88
TOMHS	0/12	0/2	*	6/656	3/232	0.71 (0.18, 2.88)	*
SYST-EUR	1/7	3/8	*	131/2361	141/2271	0.83 (0.65, 1.05)	0.26

Standing hypotension defined as SBP≤110 mm Hg or DBP≤60 mm Hg

Cox proportional hazards models adjusted for age, sex, seated systolic blood pressure, seated diastolic blood pressure, eGFR<60 mL/min per 1.73 m², body mass index, and diabetes status. Pooled estimates are additionally adjusted for study.

eTable 18. Association of baseline orthostatic hypotension with cardiovascular disease or all-cause mortality, using an alternate definition of orthostatic hypotension based on a drop in systolic blood pressure of at least 30 mm Hg or a drop in diastolic blood pressure of at least 10 mm Hg

Cardiovascular disease or all-cause							
mortality	Baseline Ortho	static Hypotension (Usir	ng Alternate Definitio	n)			
	Orthostatic	No orthostatic					
	hypotension, n/N	hypotension, n/N	HR (95% CI)	Р			
AASK	71/74	951/1015	1.17 (0.92, 1.49)	0.20			
ACCORD	10/71	135/1250	1.29 (0.68, 2.45)	0.44			
SPRINT	56/393	918/8933	1.34 (1.02, 1.76)	0.03			
SPS3	29/169	255/2176	1.56 (1.06, 2.29)	0.02			
UKPDS	36/116	275/1001	1.09 (0.77, 1.55)	0.62			
Treatment Goal Trials	202/823	2534/14375	1.28 (1.10, 1.47)	<0.001			
HYVET	38/246	488/3599	1.15 (0.82, 1.59)	0.42			
SHEP	53/254	814/4348	1.07 (0.81, 1.41)	0.63			
SYST-EUR	16/91	442/4597	1.50 (0.91, 2.47)	0.11			
TOMHS	4/37	47/865	2.04 (0.73, 5.67)	0.17			
Placebo-controlled Trials	111/628	1791/13409	1.16 (0.96, 1.41)	0.13			
All Trials*	313/1451	4325/27784	1.23 (1.10, 1.38)	<0.001			
All-Cause Mortality	Baseline Orthostatic Hypotension (Using Alternate Definition)						
	Orthostatic	No orthostatic					
	hypotension, n/N	hypotension, n/N	HR (95% CI)	Р			
AASK	8/74	98/1015	1.17 (0.57, 2.41)	0.66			
ACCORD	3/71	49/1250	1.07 (0.33, 3.45)	0.90			
SPRINT	26/393	413/8933	1.29 (0.87, 1.92)	0.20			
SPS3	15/169	111/2176	1.93 (1.12, 3.31)	0.02			
UKPDS	29/116	185/1001	1.31 (0.88, 1.93)	0.18			
Treatment Goal Trials	81/823	856/14375	1.37 (1.09, 1.73)	0.007			
HYVET	31/246	400/3599	1.14 (0.79, 1.64)	0.48			

1.81 (1.01, 3.23) TOMHS 1/37 8/865 2.99 (0.37,23.96) 0.30 Placebo-controlled Trials 81/628 1087/13409 1.37 (1.09, 1.72) 0.007 All Trials** 162/1451 1943/27784 1.37 (1.17, 1.61) < 0.001 Abbreviations: CVD, cardiovascular disease; CI, confidence interval; HR, hazard ratio; n represents number of events; N represents overall number of participants.

406/4348

273/4597

1.54 (1.10, 2.16)

0.01

0.05

Cox proportional hazards models adjusted for age, sex, and study (as a categorical variable).

SHEP

SYST-EUR

There was no evidence for an interaction by treatment arm for individual studies or pooled study groupings.

37/254

12/91

eTable 19. Treatment effects on cardiovascular disease or all-cause mortality by baseline orthostatic hypotension, using an alternate definition of orthostatic hypotension based on a drop in systolic blood pressure of at least 30 mm Hg or a drop in diastolic blood pressure of at least 10 mm Hg

			Orthostatic Hypotension			No Orthostatic Hypotension	
Cardiovascular Disease or All-cause Mortality	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	n/N (Low/Act)	n/N (Std/Pla)	HR (95% CI)	<i>P</i> -interaction
Treatment Goal Trials	102/433	100/390	0.88 (0.66, 1.16)	1218/7324	1316/7051	0.85 (0.79, 0.92)	0.88
Placebo-Controlled							
Trials	50/311	61/317	0.87 (0.59, 1.26)	798/6989	993/6420	0.74 (0.67, 0.81)	0.33
All Trials	152/744	161/707	0.88 (0.70, 1.10)	2016/14313	2309/13471	0.81 (0.76, 0.86)	0.45
All-cause Mortality							
Treatment Goal Trials	44/433	37/390	1.03 (0.66, 1.62)	417/7324	439/7051	0.82 (0.72, 0.94)	0.44
Placebo-Controlled							
Trials	35/311	46/317	0.84 (0.54, 1.31)	514/6989	573/6420	0.85 (0.76, 0.96)	0.94
All Trials	79/744	83/707	0.93 (0.68, 1.27)	931/14313	1012/13471	0.84 (0.77, 0.92)	0.56

Abbreviations: CI, confidence interval; HR, hazard ratio; Low/Act, randomized assignment of low blood pressure goal or active therapy; n represents number of events; N represents overall number of participants; Std/Pla, randomized assignment to standard blood pressure goal or placebo.

All models were adjusted for age and sex. Pooled estimates are adjusted for age, sex, and study (as a categorical variable).

Standing systolic blood pressure with thr	eshold of 110	mm Hg					
			Standing SBP ≤110			Standing SBP	
	4	4	mm Hg	1	4	>110 mm Hg	
	n/N	n/N		n/N	n/N		.
Cardiovascular Disease or Mortality	(Low/Act)	(Std/Pla)	HR (95% CI)	(Low/Act)	(Std/Pla)	HR (95% CI)	P-interaction
Treatment Goal Trials	65/305	83/308	0.80 (0.58, 1.11)	1255/7452	1333/7133	0.86 (0.79, 0.93)	0.80
Placebo-Controlled Trials	0/13	0/2	*	848/7287	1054/6735	0.74 (0.68, 0.81)	*
All Trials	65/318	83/310	0.80 (0.58, 1.11)	2103/14739	2387/13868	0.81 (0.76, 0.86)	1.00
All-cause Mortality							
Treatment Goal Trials	14/305	27/308	0.52 (0.27, 0.99)	447/7452	449/7133	0.85 (0.75, 0.97)	0.17
Placebo-Controlled Trials	0/13	0/2	*	549/7287	619/6735	0.85 (0.76, 0.96)	*
All Trials	14/318	27/310	0.52 (0.27, 0.99)	996/14739	1068/13868	0.85 (0.78, 0.93)	0.15
Standing systolic blood pressure with thr	eshold of 100	mm Hg					
			Standing SBP ≤100			Standing SBP	
			mm Hg			>100 mm Hg	
Cardiovascular Disease or Mortality			HR (95% CI)			HR (95% CI)	P -interaction
Treatment Goal Trials	12/70	20/68	0.41 (0.19, 0.89)	1308/7687	1396/7373	0.86 (0.80, 0.93)	0.19
Placebo-Controlled Trials	0/1	0/1	*	848/7299	1054/6736	0.74 (0.68, 0.81)	*
All Trials	12/71	20/69	0.41 (0.19, 0.89)	2156/14986	2450/14109	0.81 (0.77, 0.86)	0.31
All-cause Mortality							
Treatment Goal Trials	3/70	5/68	0.29 (0.06, 1.51)	458/7687	471/7373	0.84 (0.74, 0.95)	0.64
Placebo-Controlled Trials	0/1	0/1	*	549/7299	619/6736	0.85 (0.76, 0.95)	*
All Trials	3/71	5/69	0.29 (0.06, 1.51)	1007/14986	1090/14109	0.85 (0.78, 0.92)	0.65
Standing diastolic blood pressure with th	•	-	(, , ,				
			Standing DBP ≤60			Standing DBP	
			mm Hg			>60 mm Hg	
Cardiovascular Disease or Mortality			HR (95% CI)			HR (95% CI)	P -interaction
, Treatment Goal Trials	68/330	73/314	1.00 (0.71, 1.40)	1252/7427	1343/7127	0.85 (0.79, 0.92)	0.30
Placebo-Controlled Trials	21/92	24/106	1.02 (0.57, 1.85)	827/7208	1030/6631	0.74 (0.67, 0.81)	0.22
All Trials	89/422	97/420	1.00 (0.75, 1.34)	2079/14635	2373/13758	0.80 (0.76, 0.85)	0.10

eTable 20. Treatment effects on cardiovascular disease or all-cause mortality by baseline standing hypotension, defined using distinct thresholds for systolic or diastolic blood pressure

All-cause Mortality							
Treatment Goal Trials	33/330	29/314	1.26 (0.76, 2.10)	428/7427	447/7127	0.82 (0.71, 0.93)	0.15
Placebo-Controlled Trials	12/92	15/106	0.96 (0.44, 2.06)	537/7208	604/6631	0.85 (0.75, 0.95)	0.62
All Trials	45/422	44/420	1.18 (0.77, 1.81)	965/14635	1051/13758	0.84 (0.77, 0.91)	0.15
Standing diastolic blood pressure with th	reshold of 50	mm Hg					
			Standing DBP ≤50			Standing DBP	
			mm Hg			>50 mm Hg	
Cardiovascular Disease or Mortality			HR (95% CI)			HR (95% CI)	P -interaction
Treatment Goal Trials	8/44	13/46	0.71 (0.28, 1.79)	1312/7713	1403/7395	0.86 (0.80, 0.93)	0.28
Placebo-Controlled Trials	5/22	5/18	1.07 (0.28, 4.05)	843/7278	1049/6719	0.74 (0.68, 0.81)	0.71
All Trials	13/66	18/64	0.76 (0.36, 1.58)	2155/14991	2452/14114	0.81 (0.77, 0.86)	0.46
All-cause Mortality							
Treatment Goal Trials	6/44	5/46	1.53 (0.42 <i>,</i> 5.60)	455/7713	471/7395	0.83 (0.73, 0.95)	0.61
Placebo-Controlled Trials	4/22	2/18	2.54 (0.38,17.05)	545/7278	617/6719	0.85 (0.75, 0.95)	0.24
All Trials	10/66	7/64	1.87 (0.66, 5.30)	1000/14991	1088/14114	0.84 (0.77, 0.92)	0.28

All models were adjusted for age and sex. Pooled estimates are adjusted for age, sex, and study (as a categorical variable).

*Numbers too few to calculate

			Cardiovascular				
			Disease or All-cause				
		Mortality					
		n/N	HR (95% CI)	P -interaction	n/N	HR (95% CI)	P -interaction
Orthostati	c hypotension						
Age							
	≤75 years	329/1719	0.86 (0.69, 1.08)	0.67	140/1719	1.04 (0.74, 1.46)	0.36
	>75 years	172/873	0.77 (0.56, 1.04)		121/873	0.80 (0.56, 1.15)	
Sex							
	Men	288/1280	0.78 (0.62, 0.99)	0.49	144/1280	0.81 (0.58, 1.13)	0.44
	Women	213/1312	0.92 (0.70, 1.21)		117/1312	1.05 (0.73, 1.52)	
Pre-ra	andomization SBP ≥140 or DBP ≥90 mm Hg*						
	No	31/128	0.68 (0.32, 1.45)	0.74	9/128	0.40 (0.09, 1.89)	0.42
	Yes	470/2464	0.84 (0.70, 1.01)		252/2464	0.94 (0.73, 1.21)	
Diabe	etes						
	No	374/2053	0.84 (0.68, 1.03)	0.99	179/2053	0.91 (0.67, 1.22)	0.91
	Yes	127/539	0.85 (0.59, 1.21)		82/539	0.95 (0.61, 1.49)	
Stage	III chronic kidney disease*						
	≥60 mL/min per 1.73 m ²	348/1839	0.83 (0.67, 1.03)	0.98	198/1839	0.89 (0.67, 1.18)	0.62
	<60 mL/min per 1.73 m ²	148/734	0.83 (0.60, 1.15)		61/734	0.97 (0.58, 1.62)	
Body	Mass Index						
	<30 kg/m ²	241/1686	0.83 (0.64, 1.07)	0.62	124/1686	0.94 (0.65, 1.34)	0.95
	≥30 kg/m²	247/845	0.87 (0.67, 1.12)		130/845	0.91 (0.64, 1.29)	
Standing h	ypotension						
Age							
	≤75 years	193/828	0.90 (0.67, 1.19)	0.99	62/828	0.75 (0.45, 1.25)	0.59
	>75 years	111/479	0.89 (0.61, 1.30)		61/479	0.92 (0.55, 1.52)	
Sex							

eTable 21. Treatment effects among participants with baseline orthostatic hypotension or baseline standing hypotension in strata of baseline characteristics

Men	193/744	0.95 (0.71, 1.26)	0.85	80/744	0.86 (0.55, 1.35)	0.68
Women	111/563	0.97 (0.66, 1.41)		43/563	1.01 (0.55, 1.86)	
Pre-randomization SBP ≥140 or DBP ≥90 mm Hg	*					
No	138/633	0.88 (0.62, 1.23)	0.66	40/633	0.60 (0.31, 1.15)	0.12
Yes	166/674	0.99 (0.73, 1.35)		83/674	1.06 (0.68, 1.64)	
Diabetes						
No	254/1075	0.95 (0.74, 1.22)	0.78	98/1075	0.94 (0.63, 1.40)	0.55
Yes	50/232	1.01 (0.56, 1.80)		25/232	0.82 (0.36, 1.88)	
Stage III chronic kidney disease*						
≥60 mL/min per 1.73 m ²	204/874	0.98 (0.74, 1.29)	0.45	94/874	0.86 (0.57, 1.29)	0.95
<60 mL/min per 1.73 m ²	100/428	0.84 (0.56, 1.26)		29/428	0.91 (0.44, 1.92)	
Body Mass Index						
<30 kg/m ²	124/765	1.11 (0.78, 1.58)	0.23	52/765	0.97 (0.56, 1.68)	0.66
≥30 kg/m ²	175/511	0.84 (0.62, 1.14)		68/511	0.81 (0.50, 1.31)	

Abbreviations: CI, confidence interval; DBP, diastolic blood pressure; n, the number of events; HR, hazard ratio; N, the number at risk; SBP, systolic blood pressure

*Based on the CKD EPI 2021 race-free, creatinine equation. eGFR was not available from UKPDS or SHEP. UKPDS provided stage III CKD categories based on the 2021 CKD-EPI race-free, creatinine equation. For SHEP we relied on a self-reported history of kidney disease.